Zai Lab expects its first U.S. regulatory submission next year and cited the potential for its first U.S. product launch in 2028. Zai Lab expects to have three registrational programs underway by the end of 2026 across small cell lung cancer and neuroendocrine carcinoma. Amado said Zai Lab would view response rates around 80% and a 50% improvement in median progression-free survival as clinically meaningful. Zai Lab is also collaborating with Amgen and Boehringer Ingelheim on zoci combinations with T-cell engagers. About Zai Lab (NASDAQ:ZLAB)Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies.